Where are we at?
No peer review
No deal on OA
No funding
No chairman
No positive MPS results to elicit a bid from 30 pharma who were in the data room
The 1.5 mg twice weekly results are highly variable with some endpoints show a worse result than placebo. This is a dosing only 25% less than “optimal”
FDA does not think the drug is safe. On balance of risk reward on 2mg they are highly sceptical
Years of frustration. A pumper that has no gumption to caution his readership to invest so he can recover his outlay.
done
Where are we at?No peer reviewNo deal on OANo fundingNo...
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
-0.010(5.00%) |
Mkt cap ! $66.54M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.0¢ | 19.0¢ | $203.4K | 1.019M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 387930 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 65468 | 2 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |